박상윤 교수
#난소암#복막암#자궁암의 수술치료법 개발#EBS명의#헬스조선명의
|
학력
1973-03 1979-02 서울대학교 의과대학 의학과 대졸(의대)
1981-03 1983-02 서울대학교 의과대학 의학과 대학원졸(석사)
1989-09 1991-08 고려대학교 의과대학교 의학과 대학원졸(박사)
1981-03 1983-02 서울대학교 의과대학 의학과 대학원졸(석사)
1989-09 1991-08 고려대학교 의과대학교 의학과 대학원졸(박사)
경력
1979-03 1980-02 서울대학교병원 인턴
1980-03 1983-02 서울대학교병원 레지던트
1986-04 1987-02 차병원 과장
1987-04 2000-09 원자력병원 산부인과 과장
1997-07 1997-07 Washington Cancer Institute, USA Visiting doctor
1997-08 1997-08 Mainz University, Germany Visiting doctor
2000-10 2009-01 국립암센터 자궁암센터 센터장
2000-10 현재 국립암센터 자궁암센터 전문의
2001-05 2007-11 국립암센터 자궁암연구과 과장, 책임연구원
2003-04 2007-04 국립암센터 호발암연구과 부장
2007-04 2007-11 국립암센터 이행성임상연구부 부장
2007-06 2012-01 국립암센터 자궁암연구과 수석연구원
2007-12 2009-12 국립암센터 자궁암연구과 과장, 수석연구원
2011-08 2014-08 국립암센터 자궁암센터 센터장
2012-01 2017-02 국립암센터 부인암연구과 수석연구원
2017-03 2018-06 국립암센터 호발암연구과 수석연구원
2019-07 현재 국립암센터 자궁난소암센터 초빙의
1980-03 1983-02 서울대학교병원 레지던트
1986-04 1987-02 차병원 과장
1987-04 2000-09 원자력병원 산부인과 과장
1997-07 1997-07 Washington Cancer Institute, USA Visiting doctor
1997-08 1997-08 Mainz University, Germany Visiting doctor
2000-10 2009-01 국립암센터 자궁암센터 센터장
2000-10 현재 국립암센터 자궁암센터 전문의
2001-05 2007-11 국립암센터 자궁암연구과 과장, 책임연구원
2003-04 2007-04 국립암센터 호발암연구과 부장
2007-04 2007-11 국립암센터 이행성임상연구부 부장
2007-06 2012-01 국립암센터 자궁암연구과 수석연구원
2007-12 2009-12 국립암센터 자궁암연구과 과장, 수석연구원
2011-08 2014-08 국립암센터 자궁암센터 센터장
2012-01 2017-02 국립암센터 부인암연구과 수석연구원
2017-03 2018-06 국립암센터 호발암연구과 수석연구원
2019-07 현재 국립암센터 자궁난소암센터 초빙의
논문
2021 기타 The knowledge and attitude of patients diafnosed with epithelial ovarian cancer towards genetic testing: International journal of environmental research and public health. :~ (2.849)
2020 SCI-E Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial: LANCET ONCOLOGY. 21(12):1653~1660 (33.752)
2020 SCI-E Glycolytic phenotypes in an evaluation of ovarian carcinoma based on carcinogenesis and BRCA mutation.: EUROPEAN JOURNAL OF RADIOLOGY. 133:109391~ (2.687)
2020 SCI-E Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: YONSEI MEDICAL JOURNAL. 61(11):935~941 (1.914)
2020 SCI-E A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer: BRITISH JOURNAL OF CANCER. Online:Published (5.791)
2020 SCI-E The survival effect of ovary preservation in early stage endometrial cancer: a single institution retrospective analysis: JOURNAL OF OVARIAN RESEARCH. 13(1):97~ (2.989)
2020 SCI-E Uptake of Family-specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2mutation: CANCER RESEARCH AND TREATMENT. Online:Published (3.761)
2020 SCI-E Effect of addition of bevacizumab to chemoradiotherapy in newly diagnosed stage IVB cervical cancer: a single institution experience in Korea: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 30(6):764~771 (2.095)
2020 SCI-E Comprehensive geriatric assessment is correlated to overall survival among gynaecologic oncology patients: JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 50(3):276~281 (1.914)
2020 SCI-E Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study: JOURNAL OF GYNECOLOGIC ONCOLOGY. 31(2):e15~ (3.304)
2020 SCI-E Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer: CANCER RESEARCH AND TREATMENT. 52(2):396~405 (3.761)
2019 Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study: . : ()
2019 SCI Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer: THE NEW ENGLAND JOURNAL OF MEDICINE. 20:1929~1939 (70.67)
2019 SCI-E A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D: JOURNAL OF GYNECOLOGIC ONCOLOGY. Online:Published (2.914)
2019 SCI Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer: CANCER RESEARCH AND TREATMENT. Online:Published (3.363)
2019 SCI-E Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial: THE LANCET ONCOLOGY. 20(6):862~876 (35.386)2021 기타 The knowledge and attitude of patients diafnosed with epithelial ovarian cancer towards genetic testing: International journal of environmental research and public health. :~ (2.849)
2020 SCI-E Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial: LANCET ONCOLOGY. 21(12):1653~1660 (33.752)
2020 SCI-E Glycolytic phenotypes in an evaluation of ovarian carcinoma based on carcinogenesis and BRCA mutation.: EUROPEAN JOURNAL OF RADIOLOGY. 133:109391~ (2.687)
2020 SCI-E Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: YONSEI MEDICAL JOURNAL. 61(11):935~941 (1.914)
2020 SCI-E A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer: BRITISH JOURNAL OF CANCER. Online:Published (5.791)
2020 SCI-E The survival effect of ovary preservation in early stage endometrial cancer: a single institution retrospective analysis: JOURNAL OF OVARIAN RESEARCH. 13(1):97~ (2.989)
2020 SCI-E Uptake of Family-specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2mutation: CANCER RESEARCH AND TREATMENT. Online:Published (3.761)
2020 SCI-E Effect of addition of bevacizumab to chemoradiotherapy in newly diagnosed stage IVB cervical cancer: a single institution experience in Korea: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 30(6):764~771 (2.095)
2020 SCI-E Comprehensive geriatric assessment is correlated to overall survival among gynaecologic oncology patients: JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 50(3):276~281 (1.914)
2020 SCI-E Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study: JOURNAL OF GYNECOLOGIC ONCOLOGY. 31(2):e15~ (3.304)
2020 SCI-E Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer: CANCER RESEARCH AND TREATMENT. 52(2):396~405 (3.761)
2019 Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study: . : ()
2019 SCI Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer: THE NEW ENGLAND JOURNAL OF MEDICINE. 20:1929~1939 (70.67)
2019 SCI-E A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D: JOURNAL OF GYNECOLOGIC ONCOLOGY. Online:Published (2.914)
2019 SCI Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer: CANCER RESEARCH AND TREATMENT. Online:Published (3.363)
2019 SCI-E Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial: THE LANCET ONCOLOGY. 20(6):862~876 (35.386)
2019 SCI-E Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer: JAPANESE JOURNAL OF CLINICAL ONCOLOGY. Online:Published (2.183)
2019 SCI-E Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial: THE LANCET ONCOLOGY. Online:Published (35.386)
2019 SCI-E Survival outcomes of adjuvant radiotherapy and chemotherapy in women with stage I serous papillary and clear cell carcinoma of the endometrium: a Korean multicenter study: JOURNAL OF GYNECOLOGIC ONCOLOGY. 30(3):e44~e44 (2.914)
2019 SCI-E Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708): BMC CANCER. 19(1):341~341 (2.933)
2019 SCI-E Delayed IL-21 treatment preferentially expands peptide-specific CD8+ T cells by reducing bystander activation of T cells: IMMUNOTHERAPY. 11(6):497~513 (3.028)
2019 SCI Suprarenal lymph node dissection by the Kocher maneuver in the surgical management of ovarian cancer: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 29(3):647~648 (1.746)
2019 SCI Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041): GYNECOLOGIC ONCOLOGY. 152(1):61~67 (4.54)
2019 SCI-E Peritoneal cancer index in ovarian cancer: JOURNAL OF GYNECOLOGIC ONCOLOGY. 30(1):e14~e14 (2.914)
2019 SCI-E Functional loss in daily activity in ovarian cancer patients undergoing chemotherapy: Archives of Gynecology and Obstetrics. Online:Published (2.236)
2018 SCI-E Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: CANCER RESEARCH AND TREATMENT. 51(1):112~118 (3.23)
2018 SCI-E Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers: CANCER RESEARCH AND TREATMENT. 51(1):280~288 (3.23)
2018 SCI Prognostic Value of Pathologic Chemotherapy Response Score in Patients With Ovarian Cancer After Neoadjuvant Chemotherapy: International journal of gynecological cancer. 28(9):1676~1682 (2.192)
2018 SCI Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial: Gynecologic oncology. 151(1):39~45 (4.54)
2018 SCI-E Comparison of gynecologic cancer risk factors, incidence and mortality trends between South Korea and Israel, 1999-2013: Japanese journal of clinical oncology. 48(10):884~891 (2.37)
2018 SCI Treatment Results and Prognostic Factors of Brain Metastases From Ovarian Cancer: International journal of gynecological cancer. 28(8):1631~1638 (2.192)
2018 SCI-E Changes in ovarian cancer survival during the 20 years before the era of targeted therapy: BMC Cancer. 18(1):601~601 (3.288)
2018 SCI-E Current practices of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies: an international survey of oncologic surgeons: World journal of surgical oncology. 16(1):92~92 (1.792)
2018 SCI Second primary colorectal cancer among endometrial cancer survivor: shared etiology and treatment sequelae: Journal of cancer research and clinical oncology. 144(5):845~854 (3.282)
2020 SCI-E Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial: LANCET ONCOLOGY. 21(12):1653~1660 (33.752)
2020 SCI-E Glycolytic phenotypes in an evaluation of ovarian carcinoma based on carcinogenesis and BRCA mutation.: EUROPEAN JOURNAL OF RADIOLOGY. 133:109391~ (2.687)
2020 SCI-E Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: YONSEI MEDICAL JOURNAL. 61(11):935~941 (1.914)
2020 SCI-E A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer: BRITISH JOURNAL OF CANCER. Online:Published (5.791)
2020 SCI-E The survival effect of ovary preservation in early stage endometrial cancer: a single institution retrospective analysis: JOURNAL OF OVARIAN RESEARCH. 13(1):97~ (2.989)
2020 SCI-E Uptake of Family-specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2mutation: CANCER RESEARCH AND TREATMENT. Online:Published (3.761)
2020 SCI-E Effect of addition of bevacizumab to chemoradiotherapy in newly diagnosed stage IVB cervical cancer: a single institution experience in Korea: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 30(6):764~771 (2.095)
2020 SCI-E Comprehensive geriatric assessment is correlated to overall survival among gynaecologic oncology patients: JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 50(3):276~281 (1.914)
2020 SCI-E Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study: JOURNAL OF GYNECOLOGIC ONCOLOGY. 31(2):e15~ (3.304)
2020 SCI-E Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer: CANCER RESEARCH AND TREATMENT. 52(2):396~405 (3.761)
2019 Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study: . : ()
2019 SCI Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer: THE NEW ENGLAND JOURNAL OF MEDICINE. 20:1929~1939 (70.67)
2019 SCI-E A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D: JOURNAL OF GYNECOLOGIC ONCOLOGY. Online:Published (2.914)
2019 SCI Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer: CANCER RESEARCH AND TREATMENT. Online:Published (3.363)
2019 SCI-E Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial: THE LANCET ONCOLOGY. 20(6):862~876 (35.386)2021 기타 The knowledge and attitude of patients diafnosed with epithelial ovarian cancer towards genetic testing: International journal of environmental research and public health. :~ (2.849)
2020 SCI-E Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial: LANCET ONCOLOGY. 21(12):1653~1660 (33.752)
2020 SCI-E Glycolytic phenotypes in an evaluation of ovarian carcinoma based on carcinogenesis and BRCA mutation.: EUROPEAN JOURNAL OF RADIOLOGY. 133:109391~ (2.687)
2020 SCI-E Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: YONSEI MEDICAL JOURNAL. 61(11):935~941 (1.914)
2020 SCI-E A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer: BRITISH JOURNAL OF CANCER. Online:Published (5.791)
2020 SCI-E The survival effect of ovary preservation in early stage endometrial cancer: a single institution retrospective analysis: JOURNAL OF OVARIAN RESEARCH. 13(1):97~ (2.989)
2020 SCI-E Uptake of Family-specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2mutation: CANCER RESEARCH AND TREATMENT. Online:Published (3.761)
2020 SCI-E Effect of addition of bevacizumab to chemoradiotherapy in newly diagnosed stage IVB cervical cancer: a single institution experience in Korea: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 30(6):764~771 (2.095)
2020 SCI-E Comprehensive geriatric assessment is correlated to overall survival among gynaecologic oncology patients: JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 50(3):276~281 (1.914)
2020 SCI-E Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study: JOURNAL OF GYNECOLOGIC ONCOLOGY. 31(2):e15~ (3.304)
2020 SCI-E Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer: CANCER RESEARCH AND TREATMENT. 52(2):396~405 (3.761)
2019 Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study: . : ()
2019 SCI Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer: THE NEW ENGLAND JOURNAL OF MEDICINE. 20:1929~1939 (70.67)
2019 SCI-E A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D: JOURNAL OF GYNECOLOGIC ONCOLOGY. Online:Published (2.914)
2019 SCI Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer: CANCER RESEARCH AND TREATMENT. Online:Published (3.363)
2019 SCI-E Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial: THE LANCET ONCOLOGY. 20(6):862~876 (35.386)
2019 SCI-E Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer: JAPANESE JOURNAL OF CLINICAL ONCOLOGY. Online:Published (2.183)
2019 SCI-E Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial: THE LANCET ONCOLOGY. Online:Published (35.386)
2019 SCI-E Survival outcomes of adjuvant radiotherapy and chemotherapy in women with stage I serous papillary and clear cell carcinoma of the endometrium: a Korean multicenter study: JOURNAL OF GYNECOLOGIC ONCOLOGY. 30(3):e44~e44 (2.914)
2019 SCI-E Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708): BMC CANCER. 19(1):341~341 (2.933)
2019 SCI-E Delayed IL-21 treatment preferentially expands peptide-specific CD8+ T cells by reducing bystander activation of T cells: IMMUNOTHERAPY. 11(6):497~513 (3.028)
2019 SCI Suprarenal lymph node dissection by the Kocher maneuver in the surgical management of ovarian cancer: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 29(3):647~648 (1.746)
2019 SCI Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041): GYNECOLOGIC ONCOLOGY. 152(1):61~67 (4.54)
2019 SCI-E Peritoneal cancer index in ovarian cancer: JOURNAL OF GYNECOLOGIC ONCOLOGY. 30(1):e14~e14 (2.914)
2019 SCI-E Functional loss in daily activity in ovarian cancer patients undergoing chemotherapy: Archives of Gynecology and Obstetrics. Online:Published (2.236)
2018 SCI-E Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: CANCER RESEARCH AND TREATMENT. 51(1):112~118 (3.23)
2018 SCI-E Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers: CANCER RESEARCH AND TREATMENT. 51(1):280~288 (3.23)
2018 SCI Prognostic Value of Pathologic Chemotherapy Response Score in Patients With Ovarian Cancer After Neoadjuvant Chemotherapy: International journal of gynecological cancer. 28(9):1676~1682 (2.192)
2018 SCI Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial: Gynecologic oncology. 151(1):39~45 (4.54)
2018 SCI-E Comparison of gynecologic cancer risk factors, incidence and mortality trends between South Korea and Israel, 1999-2013: Japanese journal of clinical oncology. 48(10):884~891 (2.37)
2018 SCI Treatment Results and Prognostic Factors of Brain Metastases From Ovarian Cancer: International journal of gynecological cancer. 28(8):1631~1638 (2.192)
2018 SCI-E Changes in ovarian cancer survival during the 20 years before the era of targeted therapy: BMC Cancer. 18(1):601~601 (3.288)
2018 SCI-E Current practices of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies: an international survey of oncologic surgeons: World journal of surgical oncology. 16(1):92~92 (1.792)
2018 SCI Second primary colorectal cancer among endometrial cancer survivor: shared etiology and treatment sequelae: Journal of cancer research and clinical oncology. 144(5):845~854 (3.282)
저서
저서 내용이 없습니다.
보도자료
국립암센터 박상윤 교수가 알려준 난소암을 대하는 법
http://woman.chosun.com/client/news/viw.asp?cate=C01&mcate=M1003&nNewsNumb=20200768231
암치료 어떻게 할까 8 난소암
https://www.nocutnews.co.kr/news/4264855
[내 생애 최고의 수술]<6>난소암 수술 2000여회 집도한 박상윤 교수
https://www.donga.com/news/article/all/20110725/39049703/1
http://woman.chosun.com/client/news/viw.asp?cate=C01&mcate=M1003&nNewsNumb=20200768231
암치료 어떻게 할까 8 난소암
https://www.nocutnews.co.kr/news/4264855
[내 생애 최고의 수술]<6>난소암 수술 2000여회 집도한 박상윤 교수
https://www.donga.com/news/article/all/20110725/39049703/1
포스팅
포스팅 내용이 없습니다.
영상자료
난소암 수술, 세계 최고를 넘보다-산부인과 전문의 박상윤
https://home.ebs.co.kr/bestdoctors/vodReplayView?siteCd=ME&courseId=BP0PAPG0000000014&stepId=01BP0PAPG0000000014&lectId=3078128
[MBN] [특집다큐H]여성 건강의 질을 높여라!
https://www.mbn.co.kr/vod/programContents/previewlist/822/5212/1259957
[의학채널 비온뒤] [홍혜걸의 인사이트 인터뷰] #7 난소암의 대가 - 국립암센터 박상윤 교수
https://www.youtube.com/watch?v=5OxhwXVeofk
[EBS 명의] 난소암 수술, 세계 최고를 넘보다-산부인과 전문의 박상윤
https://bestdoctors.ebs.co.kr/bestdoctors/vodReplayView?siteCd=ME&prodId=454&courseId=BP0PAPG0000000014&stepId=01BP0PAPG0000000014&lectId=3078128
https://home.ebs.co.kr/bestdoctors/vodReplayView?siteCd=ME&courseId=BP0PAPG0000000014&stepId=01BP0PAPG0000000014&lectId=3078128
[MBN] [특집다큐H]여성 건강의 질을 높여라!
https://www.mbn.co.kr/vod/programContents/previewlist/822/5212/1259957
[의학채널 비온뒤] [홍혜걸의 인사이트 인터뷰] #7 난소암의 대가 - 국립암센터 박상윤 교수
https://www.youtube.com/watch?v=5OxhwXVeofk
[EBS 명의] 난소암 수술, 세계 최고를 넘보다-산부인과 전문의 박상윤
https://bestdoctors.ebs.co.kr/bestdoctors/vodReplayView?siteCd=ME&prodId=454&courseId=BP0PAPG0000000014&stepId=01BP0PAPG0000000014&lectId=3078128
발표자료
발표자료 내용이 없습니다.